Tags

Type your tag names separated by a space and hit enter

The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
Cancer Chemother Pharmacol 2003; 51(4):306-10CC

Abstract

PURPOSE

Monohydroxyethylrutoside (monoHER) has proved to be a good protector against doxorubicin-induced cardiotoxicity without interfering with the antitumor effect of doxorubicin. The aim of the present study was to determine whether there is a pharmacokinetic interaction between monoHER and doxorubicin which may be involved in monoHER cardioprotection.

METHODS

Mice were treated with monoHER (500 mg x kg(-1) i.v.) alone, monoHER 5 min after doxorubicin (10 mg x kg(-1) i.v.), doxorubicin alone and doxorubicin 5 min after monoHER. The levels of monoHER and doxorubicin(ol) in plasma and heart tissue were measured by HPLC 24 h and 48 h after monoHER and doxorubicin administration, respectively.

RESULTS

The areas under the concentration-time curves (AUCs) of monoHER and doxorubicin(ol) were not affected by the coadministered drug. No changes were observed in pharmacokinetic parameters such as initial and final half-lives, mean residence time, clearance and volume of distribution of monoHER and doxorubicin(ol) after single or combined administration.

CONCLUSION

The cardioprotection of monoHER in mice is not caused by a pharmacokinetic interaction between monoHER and doxorubicin.

Authors+Show Affiliations

Department of Medical Oncology, Clinical Research Laboratory of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. m.abulhassan@vumc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12721758

Citation

Abou El Hassan, Mohamed A I., et al. "The Cardioprotector monoHER Does Not Interfere With the Pharmacokinetics or the Metabolism of the Cardiotoxic Agent Doxorubicin in Mice." Cancer Chemotherapy and Pharmacology, vol. 51, no. 4, 2003, pp. 306-10.
Abou El Hassan MA, Kedde MA, Zwiers UT, et al. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. Cancer Chemother Pharmacol. 2003;51(4):306-10.
Abou El Hassan, M. A., Kedde, M. A., Zwiers, U. T., Bast, A., & van der Vijgh, W. J. (2003). The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. Cancer Chemotherapy and Pharmacology, 51(4), pp. 306-10.
Abou El Hassan MA, et al. The Cardioprotector monoHER Does Not Interfere With the Pharmacokinetics or the Metabolism of the Cardiotoxic Agent Doxorubicin in Mice. Cancer Chemother Pharmacol. 2003;51(4):306-10. PubMed PMID: 12721758.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. AU - Abou El Hassan,Mohamed A I, AU - Kedde,Marc A, AU - Zwiers,Ursula T H, AU - Bast,Aalt, AU - van der Vijgh,Wim J F, Y1 - 2003/03/22/ PY - 2002/10/21/received PY - 2003/01/09/accepted PY - 2003/5/2/pubmed PY - 2003/6/28/medline PY - 2003/5/2/entrez SP - 306 EP - 10 JF - Cancer chemotherapy and pharmacology JO - Cancer Chemother. Pharmacol. VL - 51 IS - 4 N2 - PURPOSE: Monohydroxyethylrutoside (monoHER) has proved to be a good protector against doxorubicin-induced cardiotoxicity without interfering with the antitumor effect of doxorubicin. The aim of the present study was to determine whether there is a pharmacokinetic interaction between monoHER and doxorubicin which may be involved in monoHER cardioprotection. METHODS: Mice were treated with monoHER (500 mg x kg(-1) i.v.) alone, monoHER 5 min after doxorubicin (10 mg x kg(-1) i.v.), doxorubicin alone and doxorubicin 5 min after monoHER. The levels of monoHER and doxorubicin(ol) in plasma and heart tissue were measured by HPLC 24 h and 48 h after monoHER and doxorubicin administration, respectively. RESULTS: The areas under the concentration-time curves (AUCs) of monoHER and doxorubicin(ol) were not affected by the coadministered drug. No changes were observed in pharmacokinetic parameters such as initial and final half-lives, mean residence time, clearance and volume of distribution of monoHER and doxorubicin(ol) after single or combined administration. CONCLUSION: The cardioprotection of monoHER in mice is not caused by a pharmacokinetic interaction between monoHER and doxorubicin. SN - 0344-5704 UR - https://www.unboundmedicine.com/medline/citation/12721758/The_cardioprotector_monoHER_does_not_interfere_with_the_pharmacokinetics_or_the_metabolism_of_the_cardiotoxic_agent_doxorubicin_in_mice_ L2 - https://dx.doi.org/10.1007/s00280-003-0582-3 DB - PRIME DP - Unbound Medicine ER -